Aptevo (APVO) Director Grant Grady III Receives Award

What Happened Grant Grady III, a director of Aptevo Therapeutics (APVO), had 400 restricted stock units (RSUs) convert into 400 common shares on August 6, 2026 (reported as an exercise/conversion of a derivative). The filing also shows a simultaneous disposition of 400 shares at $0.00. The filing includes no cash proceeds — this is a vesting/settlement event, not an open-market buy or sale.

Key Details

• Transaction date: August 6, 2026; Form 4 filed August 10, 2026.
• Reported transactions: 400 shares acquired via conversion (derivative code M) and 400 shares disposed at $0.00 (derivative).
• Price/Value: $0.00 reported on the disposition; no sale proceeds disclosed.
• Shares owned after the transaction: not specified in the provided filing excerpt.
• Relevant footnotes:
  • F1: RSUs convert one-for-one into common stock (par value $0.001).
  • F2: These RSUs were part of a grant on August 6, 2025 (7,200 original; 400 post-split) that vested on the first anniversary.
• Timeliness: The Form 4 was filed four days after the reported transaction date; Form 4s are generally due within two business days, so this appears late.

Context

• This was a vesting/settlement of RSUs rather than a purchase or market sale. The zero-dollar disposition is commonly used to report shares withheld to cover taxes at vesting; the filing format here shows both the conversion and the withheld shares.
• Such award/withholding transactions do not necessarily indicate a change in an insider’s view of the company’s prospects (they are often routine tax/settlement actions).